Lucid Diagnostics Inc. 8-K

What Happened

• On April 24, 2026, Lucid Diagnostics Inc. announced the closing of an underwritten public offering in which it sold 18,000,000 shares of common stock at $1.00 per share.
• The offering was conducted under the company’s Form S-3 shelf (filed Dec 5, 2025; declared effective Mar 26, 2026) with a final prospectus supplement dated April 23, 2026. Canaccord Genuity LLC and BTIG, LLC served as joint bookrunners.
• Gross proceeds were $18.0 million; net proceeds after underwriting discounts and estimated expenses are expected to be approximately $16.8 million. The company said it intends to use the net proceeds for working capital and general corporate purposes. A press release announcing the closing was furnished as Exhibit 99.1.

Key Details

• Sold: 18,000,000 shares of common stock
• Offering price: $1.00 per share
• Expected net proceeds: ~ $16.8 million
• Date of closing and disclosure: April 24, 2026; prospectus supplement filed April 23, 2026

Why It Matters

• The transaction provides Lucid with fresh cash (about $16.8M net), which management plans to deploy for working capital and general corporate needs—important for funding operations and near-term plans.
• Issuing 18 million new shares dilutes existing shareholders; investors should consider the impact on share count and per-share metrics when assessing the company going forward.
• The offering was completed under an existing S-3 shelf, indicating the company had registration capacity in place to raise capital efficiently.